---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-014819"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:54:15.170861+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Catalyst Biosciences amends business combination agreement, extends outside date to Sept 30, 2023

## Summary
- Extended outside date for business combination with GNI Group to September 30, 2023.
- Operating company options to be replaced with options under Parent's 2023 Omnibus Incentive Plan.
- Contributors to reimburse Catalyst for operating expenses over $500k up to $1M, and all expenses from July 20, 2023 to closing.
- Amended F351 asset purchase agreement extends deadline for cash settlement of conversion shares to September 30, 2023.
- Amended Contingent Value Rights Agreement to reflect sale of certain assets under GCB APA.

## SEC filing metadata
- accession: 0001140361-23-014819
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-014819
- JSON: https://secwatch.observer/filing/0001140361-23-014819.json
- Plain text: https://secwatch.observer/filing/0001140361-23-014819.txt

## Key facts
- Material Agreements
  GYRE THERAPEUTICS, INC. amended CVR Agreement Amendment (effective 2023-03-29).
  - Action: amendment
  - Effective: 2023-03-29
  source text: On March 29, 2023, Catalyst executed an amendment to Contingent Value Rights Agreement (the “ CVR Agreement Amendment ”) to the previously announced Contingent Value Rights Agreement, dated as of December 26, 2022 (the “ CVR Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm
- Material Agreements
  GYRE THERAPEUTICS, INC. amended Agreement and Amendment with Catalyst, GNI Group and GNI HK (effective 2023-03-29).
  - Action: amendment
  - Agreement: asset purchase
  - Counterparty: Catalyst, GNI Group and GNI HK
  - Effective: 2023-03-29
  source text: On March 29, 2023, Catalyst, GNI Group and GNI HK entered into an agreement and amendment (the “ Agreement and Amendment ”) to the previously announced Asset Purchase Agreement, dated as of December 26, 2022 (the “ F351 Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm
- Material Agreements
  GYRE THERAPEUTICS, INC. amended BCA Amendment with Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc. (effective 2023-03-29).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc.
  - Effective: 2023-03-29
  source text: On March 29, 2023, Catalyst Biosciences, Inc., a Delaware corporation (“ Catalyst ”), GNI USA, Inc., a Delaware corporation (“ GNI USA ”), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“ GNI Group ”), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (“ GNI HK ”), Shanghai Genomics, Inc., a company organized under the laws of the People’s Republic of China (“ Shanghai Genomics ”, and collectively with GNI USA, GNI Group and GNI HK, the “ Contributors ,” and each a “ Contributor ”), the individuals (each, a “ Minority Holder ” and collectively, the “ Minority Holders ”) listed on Annex A thereto and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (the “ CPI ”), entered into an amendment (the “ BCA Amendment ”) to the previously announced Business Combination Agreement, dated as of December 26, 2022 (the “ Business Combination Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.